IBDEI1RL ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,28186,1,4,0)
 ;;=4^T43.206A
 ;;^UTILITY(U,$J,358.3,28186,2)
 ;;=^5050543
 ;;^UTILITY(U,$J,358.3,28187,0)
 ;;=T43.206S^^113^1379^7
 ;;^UTILITY(U,$J,358.3,28187,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28187,1,3,0)
 ;;=3^Underdosing of Antidepressants,Sequela
 ;;^UTILITY(U,$J,358.3,28187,1,4,0)
 ;;=4^T43.206S
 ;;^UTILITY(U,$J,358.3,28187,2)
 ;;=^5050545
 ;;^UTILITY(U,$J,358.3,28188,0)
 ;;=T43.206D^^113^1379^8
 ;;^UTILITY(U,$J,358.3,28188,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28188,1,3,0)
 ;;=3^Underdosing of Antidepressants,Subs Encntr
 ;;^UTILITY(U,$J,358.3,28188,1,4,0)
 ;;=4^T43.206D
 ;;^UTILITY(U,$J,358.3,28188,2)
 ;;=^5050544
 ;;^UTILITY(U,$J,358.3,28189,0)
 ;;=T43.506A^^113^1379^12
 ;;^UTILITY(U,$J,358.3,28189,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28189,1,3,0)
 ;;=3^Underdosing of Antipsychotics & Neuroleptics,Init Encntr
 ;;^UTILITY(U,$J,358.3,28189,1,4,0)
 ;;=4^T43.506A
 ;;^UTILITY(U,$J,358.3,28189,2)
 ;;=^5050651
 ;;^UTILITY(U,$J,358.3,28190,0)
 ;;=T43.506S^^113^1379^13
 ;;^UTILITY(U,$J,358.3,28190,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28190,1,3,0)
 ;;=3^Underdosing of Antipsychotics & Neuroleptics,Sequela
 ;;^UTILITY(U,$J,358.3,28190,1,4,0)
 ;;=4^T43.506S
 ;;^UTILITY(U,$J,358.3,28190,2)
 ;;=^5050653
 ;;^UTILITY(U,$J,358.3,28191,0)
 ;;=T43.506D^^113^1379^14
 ;;^UTILITY(U,$J,358.3,28191,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28191,1,3,0)
 ;;=3^Underdosing of Antipsychotics & Neuroleptics,Subs Encntr
 ;;^UTILITY(U,$J,358.3,28191,1,4,0)
 ;;=4^T43.506D
 ;;^UTILITY(U,$J,358.3,28191,2)
 ;;=^5050652
 ;;^UTILITY(U,$J,358.3,28192,0)
 ;;=99605^^114^1380^1^^^^1
 ;;^UTILITY(U,$J,358.3,28192,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,28192,1,2,0)
 ;;=2^MTMS BY PHARM,INIT 15 MIN
 ;;^UTILITY(U,$J,358.3,28192,1,3,0)
 ;;=3^99605
 ;;^UTILITY(U,$J,358.3,28193,0)
 ;;=99607^^114^1380^2^^^^1
 ;;^UTILITY(U,$J,358.3,28193,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,28193,1,2,0)
 ;;=2^MTMS BY PHARM, EA ADDL 15 MIN
 ;;^UTILITY(U,$J,358.3,28193,1,3,0)
 ;;=3^99607
 ;;^UTILITY(U,$J,358.3,28194,0)
 ;;=99606^^114^1381^1^^^^1
 ;;^UTILITY(U,$J,358.3,28194,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,28194,1,2,0)
 ;;=2^MTMS BY PHARM,INIT 15 MIN
 ;;^UTILITY(U,$J,358.3,28194,1,3,0)
 ;;=3^99606
 ;;^UTILITY(U,$J,358.3,28195,0)
 ;;=99607^^114^1381^2^^^^1
 ;;^UTILITY(U,$J,358.3,28195,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,28195,1,2,0)
 ;;=2^MTMS BY PHARM, EA ADDL 15 MIN
 ;;^UTILITY(U,$J,358.3,28195,1,3,0)
 ;;=3^99607
 ;;^UTILITY(U,$J,358.3,28196,0)
 ;;=98960^^114^1382^1^^^^1
 ;;^UTILITY(U,$J,358.3,28196,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,28196,1,2,0)
 ;;=2^INDIVIDUAL PATIENT, EA 30 MIN
 ;;^UTILITY(U,$J,358.3,28196,1,3,0)
 ;;=3^98960
 ;;^UTILITY(U,$J,358.3,28197,0)
 ;;=98961^^114^1382^2^^^^1
 ;;^UTILITY(U,$J,358.3,28197,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,28197,1,2,0)
 ;;=2^2-4 PATIENTS, EA 30 MIN
 ;;^UTILITY(U,$J,358.3,28197,1,3,0)
 ;;=3^98961
 ;;^UTILITY(U,$J,358.3,28198,0)
 ;;=98962^^114^1382^3^^^^1
 ;;^UTILITY(U,$J,358.3,28198,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,28198,1,2,0)
 ;;=2^5-8 PATIENTS, EA 30 MIN
 ;;^UTILITY(U,$J,358.3,28198,1,3,0)
 ;;=3^98962
 ;;^UTILITY(U,$J,358.3,28199,0)
 ;;=T74.11XA^^115^1383^7
 ;;^UTILITY(U,$J,358.3,28199,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28199,1,3,0)
 ;;=3^Adult Physical Abuse,Confirmed,Init Enctr
